NikoleV Posted September 24, 2012 Share Posted September 24, 2012 ASCO 2012 Highlights: Exploring Adjuvant Tarceva for EGFR Mutation-Positive Resected NSCLC September 24th, 2012 - by Dr. Jack West http://blog.lungevity.org/2012/09/24/se ... ighlights/ Dr. Neal led a provocative clinical trial that he presented at ASCO 2012, so it’s only fitting that he also provided a summary of the work and its implications in our program onLung Cancer Highlights from that meeting. SELECT is a phase II trial that looked at adjuvant (post-operative) Tarceva (erlotinib) for patients with resected early stage EGFR mutation-positive NSCLC. Results were preliminary, and it’s a single armed trial, but it revealed several important concepts about feasibility and the potential utility of post-operative Tarceva for this patient population. Here are the podcasts from his summary of this work, in both video and audio versions formats. Below are also the transcript and figures for the program. Click on the link above to view the podcasts. Dr. Neal LC Highlights ASCO 2012 SELECT Trial Adjuvant Tarceva Video Podcast Dr. Neal LC Highlights ASCO 2012 SELECT Trial Adjuvant Tarceva Audio Podcast Dr. Neal LC Highlights ASCO 2012 SELECT Trial Adjuvant Tarceva Figs Dr. Neal LC Highlights ASCO 2012 SELECT Trial Adjuvant Tarceva Transcript The final topic of discussion will be appearing here shortly, on molecular targets for squamous NSCLC. We’ll then finish the ASCO Highlights series with the question and answer session that followed the presentations by Drs. Socinski and Neal. Look for those soon. Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.